Gilead Sciences, Inc.SEC Filings
|
|
All SEC filings by Gilead Sciences, Inc. (GILD) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 6, 2026 | |
| 10-Q | Quarterly report | View Diff | May 7, 2026 | |
| ARS | Annual report to shareholders | Mar 20, 2026 | ||
| 10-K | Annual report | View Diff | Feb 24, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 7, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 7, 2025 | |
| 10-Q | Quarterly report | View Diff | May 7, 2025 | |
| ARS | Annual report to shareholders | Mar 27, 2025 | ||
| 10-K | Annual report | View Diff | Feb 28, 2025 | |
| 10-Q | Quarterly report | View Diff | Nov 12, 2024 |
Events
| 8-K | Gilead Sciences Announces Second Quarter 2026 Financial Results | Aug 4, 2026 | ||
| 8-K | Entry Into a Material Definitive Agreement | May 20, 2026 | ||
| 8-K | Gilead Sciences Announces First Quarter Financial Results | May 7, 2026 | ||
| 8-K | Submission of Matters to a Vote of Security Holders | May 4, 2026 | ||
| 8-K | Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-Cel | Apr 28, 2026 | ||
| 8-K | Entry Into a Material Definitive Agreement | Feb 23, 2026 | ||
| 8-K | Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results | Feb 10, 2026 | ||
| 8-K | Departure of Directors or Certain Officers | Nov 19, 2025 | ||
| 8-K | Gilead Sciences Announces Third Quarter 2025 Financial Results | Oct 30, 2025 | ||
| 8-K | Regulation Fd Disclosure | Oct 6, 2025 |
Registrations and Prospectuses
| S-3ASR | Automatic shelf registration | Aug 6, 2026 | ||
| 424B5 | Prospectus supplement for primary offering | May 18, 2026 | ||
| FWP | Free writing prospectus | May 14, 2026 | ||
| FWP | Free writing prospectus | May 14, 2026 | ||
| 424B5 | Prospectus supplement for primary offering | May 14, 2026 | ||
| S-8 | Registration of securities for employees | May 7, 2026 | ||
| SC TO-T/A | Third party tender offer statement | Apr 28, 2026 | ||
| SC TO-T/A | Third party tender offer statement | Apr 17, 2026 | ||
| SC TO-T/A | Third party tender offer statement | Apr 1, 2026 | ||
| SC TO-T | Third party tender offer statement | Mar 6, 2026 |
Proxies
| N-PX | Annual report of proxy voting record | Aug 26, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Mar 20, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | Mar 20, 2026 | |
| N-PX | Annual report of proxy voting record | Aug 29, 2025 | ||
| PX14A6G | Letter to shareholders | Apr 7, 2025 | ||
| DEFA14A | Additional proxy soliciting materials | Mar 27, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Mar 27, 2025 | |
| DEFA14A | Additional proxy soliciting materials | Mar 28, 2024 | ||
| DEF 14A | Definitive proxy | View Diff | Mar 28, 2024 | |
| PRE 14A | Preliminary proxy | Mar 18, 2024 |
Other
| CORRESP | Correspondence with SEC | Mar 11, 2024 | ||
| UPLOAD | Letter from SEC | May 5, 2023 | ||
| CORRESP | Correspondence with SEC | Apr 25, 2023 | ||
| UPLOAD | Letter from SEC | Mar 29, 2023 | ||
| CT ORDER | Confidential treatment order | Feb 2, 2022 | ||
| CORRESP | Correspondence with SEC | Oct 2, 2020 | ||
| CT ORDER | Confidential treatment order | Apr 14, 2020 | ||
| CT ORDER | Confidential treatment order | Apr 14, 2020 | ||
| CT ORDER | Confidential treatment order | Apr 14, 2020 | ||
| CT ORDER | Confidential treatment order | Jan 28, 2020 |
Ownership
| 4 | O'Day Daniel Patrick | Sep 2, 2026 | ||
| 4 | Welters Anthony | Aug 27, 2026 | ||
| 144 | Notice of proposed sale of securities | Aug 26, 2026 | ||
| 4 | Bluestone Jeffrey | Aug 21, 2026 | ||
| 144 | Notice of proposed sale of securities | Aug 20, 2026 | ||
| 4 | Dickinson Andrew D | Aug 18, 2026 | ||
| 4 | Mercier Johanna | Aug 18, 2026 | ||
| 144 | Notice of proposed sale of securities | Aug 17, 2026 | ||
| 144 | Notice of proposed sale of securities | Aug 17, 2026 | ||
| 4 | Cain Wettan Keeley M | Aug 11, 2026 |